Statement Of Cash Flows [Abstract]
| Concept |
2024-01-01 to 2024-12-31 |
2023-01-01 to 2023-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Adjustments for finance income (cost) |
211,000,000
EUR
|
173,000,000
EUR
|
| Increase (decrease) in working capital |
283,000,000
EUR
|
300,000,000
EUR
|
| Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss |
1 246
EUR
|
1 303
EUR
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
421,000,000
EUR
|
209,000,000
EUR
|
| Adjustments for undistributed profits of investments accounted for using equity method |
52,000,000
EUR
|
136,000,000
EUR
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of interests in investments accounted for using equity method |
1,000,000
EUR
|
5,000,000
EUR
|
| Purchase of biological assets |
103,000,000
EUR
|
92,000,000
EUR
|
| Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
1 010
EUR
|
897,000,000
EUR
|
| Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
23,000,000
EUR
|
47,000,000
EUR
|
| Proceeds from sales or maturity of financial instruments, classified as investing activities |
3,000,000
EUR
|
0
EUR
|
| Cash flows from (used in) financing activities [abstract] | ||
| Proceeds from non-current borrowings |
19,000,000
EUR
|
2 006
EUR
|